financetom
Business
financetom
/
Business
/
RattanIndia Power Ltd. raises fresh loan of Rs. 1,114 Crores
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RattanIndia Power Ltd. raises fresh loan of Rs. 1,114 Crores
Jun 24, 2023 11:53 PM

RattanIndia Power Ltd. has raised a loan of Rs. 1,114 Crores in a transaction led by Kotak Mahindra Bank. The thermal power company had earlier concluded a resolution with erstwhile lenders for 1,350 MW Amravati Thermal Power Plant in December 2019, whereby the loans from Indian banks and financial institutions were taken over by international financial institutions including Goldman Sachs and Varde Partners through Aditya Birla ARC along with 15 percent equity stake each to both sets of lenders (outgoing and incoming).

Share Market Live

NSE

Since December 2019, RattanIndia Power Ltd. has repaid an amount of Rs. 3,371 Crores over last three and a half years to these international financial institutions, out of which Rs. 988 Crores was prepayment.

RattanIndia Power Ltd. has raised fresh loan of Rs. 1,114 Crores in a transaction led by Kotak Mahindra Bank and has fully repaid the balance senior debt to these foreign financial institutions.

In recent developments, a Kotak Mahindra Bank arm on June 23 said it invested Rs 732 crore in the non-convertible debentures (NCDs) of RattanIndia Power Ltd (RIPL).

RattanIndia Power is one of the few private sector thermal power generators supplying power to Maharashtra State Electricity Distribution Company.

Company’s operational performance remains strong with average EBITDA exceeding Rs 1,000 Crores per annum since commissioning over the last 8 years. 1,350 MW Amravati Power Plant has full PPA with Maharashtra discom MSEDCL and full coal linkage with Coal India subsidiary South Eastern Coalfields Ltd, the company said in a press release to the exchanges.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blue Bird Insider Sold Shares Worth $822,244, According to a Recent SEC Filing
Blue Bird Insider Sold Shares Worth $822,244, According to a Recent SEC Filing
Dec 18, 2024
03:06 PM EST, 12/18/2024 (MT Newswires) -- Razvan Radulescu, Chief Financial Officer, on December 17, 2024, sold 19,171 shares in Blue Bird ( BLBD ) for $822,244. Following the Form 4 filing with the SEC, Radulescu has control over a total of 89,347 shares of the company, with 89,347 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1589526/000158952624000140/xslF345X05/wk-form4_1734552169.xml Price: 43.02, Change: -1.36, Percent...
--Great Southern Bancorp Keeps Quarterly Dividend at $0.40 a Share, Payable Jan. 14 to Shareholders of Record on Dec. 30
--Great Southern Bancorp Keeps Quarterly Dividend at $0.40 a Share, Payable Jan. 14 to Shareholders of Record on Dec. 30
Dec 18, 2024
02:58 PM EST, 12/18/2024 (MT Newswires) -- Price: 64.42, Change: -0.37, Percent Change: -0.57 ...
Trane Technologies' Growth Outlook Intact Amid Short-Cycle Acceleration, UBS Says
Trane Technologies' Growth Outlook Intact Amid Short-Cycle Acceleration, UBS Says
Dec 18, 2024
02:57 PM EST, 12/18/2024 (MT Newswires) -- Trane Technologies's ( TT ) growth algorithm remains unchanged with top quartile growth expected for 2025 earnings and revenue, UBS Securities said in an earnings preview Wednesday. The investment firm said it expects EPS growth of 12% to 15% and revenue growth in the mid-to-high single digits in 2025 as well as an...
Pfizer 2025 Guidance Signals Relief to Investors, UBS Says
Pfizer 2025 Guidance Signals Relief to Investors, UBS Says
Dec 18, 2024
03:07 PM EST, 12/18/2024 (MT Newswires) -- Pfizer's ( PFE ) initial 2025 guidance signals relief to investors as it highlights stabilizing business with improving margins, UBS said in a note emailed Wednesday. Pfizer ( PFE ) on Tuesday projected higher earnings for 2025 and revenue in line with this year's likely result as the pharmaceutical giant looks to continue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved